Key result
Provided text contains only journal editorial board information with no clinical study data.
Why the study?
Does rivaroxaban prevent stroke, transient ischaemic attack, or systemic embolism in daily-care patients with atrial fibrillation?
Does rivaroxaban prevent stroke, transient ischaemic attack, or systemic embolism in daily-care patients with atrial fibrillation?
Real-world registry data confirms the effectiveness and relative safety of rivaroxaban for stroke prevention in atrial fibrillation, with lower discontinuation rates than historically reported for vitamin K antagonists.
No takes yet. Share an insight, caveat, or question.
Low event rates on rivaroxaban in routine AF care; leaves open need for randomized comparisons.
Hecker et al. (2016) studied atrial fibrillation. rivaroxaban was evaluated. No clinical study data is available in the provided text, which only contains the journal's editorial board information.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: